Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone product… Read more
Meta Biomed Co. Ltd (059210) - Total Assets
Latest total assets as of September 2025: ₩180.11 Billion KRW
Based on the latest financial reports, Meta Biomed Co. Ltd (059210) holds total assets worth ₩180.11 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Meta Biomed Co. Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Meta Biomed Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Meta Biomed Co. Ltd's total assets of ₩180.11 Billion consist of 53.0% current assets and 47.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩14.52 Billion | 8.2% |
| Accounts Receivable | ₩13.38 Billion | 7.6% |
| Inventory | ₩18.77 Billion | 10.6% |
| Property, Plant & Equipment | ₩64.10 Billion | 36.2% |
| Intangible Assets | ₩824.25 Million | 0.5% |
| Goodwill | ₩1.01 Billion | 0.6% |
Asset Composition Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Meta Biomed Co. Ltd's current assets represent 53.0% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 8.2% of total assets in 2024, up from 3.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 36.2% of total assets.
Meta Biomed Co. Ltd Competitors by Total Assets
Key competitors of Meta Biomed Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
InBody Co.Ltd
KQ:041830
|
Korea | ₩318.34 Billion |
|
MEDIANA Co.Ltd
KQ:041920
|
Korea | ₩147.44 Billion |
|
Value Added Technology Co. Ltd
KQ:043150
|
Korea | ₩658.61 Billion |
|
MEKICS Co Ltd
KQ:058110
|
Korea | ₩55.71 Billion |
|
INFINITT Healthcare Co. Ltd
KQ:071200
|
Korea | ₩229.14 Billion |
|
i-SENS Inc
KQ:099190
|
Korea | ₩583.47 Billion |
|
Sewoon Medical Co. Ltd
KQ:100700
|
Korea | ₩158.77 Billion |
|
CU Medical Systems Inc
KQ:115480
|
Korea | ₩104.65 Billion |
Meta Biomed Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Meta Biomed Co. Ltd generates 0.53x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Meta Biomed Co. Ltd generates $ 12.64 in net profit.
Meta Biomed Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.55 | 1.18 | 1.10 |
| Quick Ratio | 1.14 | 0.98 | 0.74 |
| Cash Ratio | 0.00 | 0.19 | 0.00 |
| Working Capital | ₩31.34 Billion | ₩ 12.84 Billion | ₩ 4.71 Billion |
Meta Biomed Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Meta Biomed Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.13 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 36.3% |
| Total Assets | ₩177.30 Billion |
| Market Capitalization | $51.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Meta Biomed Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Meta Biomed Co. Ltd's assets grew by 36.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Meta Biomed Co. Ltd (2011–2024)
The table below shows the annual total assets of Meta Biomed Co. Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩177.30 Billion | +36.25% |
| 2023-12-31 | ₩130.12 Billion | +7.48% |
| 2022-12-31 | ₩121.07 Billion | +17.40% |
| 2021-12-31 | ₩103.13 Billion | -4.38% |
| 2020-12-31 | ₩107.86 Billion | +4.42% |
| 2019-12-31 | ₩103.29 Billion | +5.73% |
| 2018-12-31 | ₩97.69 Billion | -18.36% |
| 2017-12-31 | ₩119.66 Billion | -0.34% |
| 2016-12-31 | ₩120.08 Billion | +5.53% |
| 2015-12-31 | ₩113.78 Billion | -1.11% |
| 2014-12-31 | ₩115.06 Billion | -1.48% |
| 2013-12-31 | ₩116.79 Billion | +12.91% |
| 2012-12-31 | ₩103.43 Billion | +91.93% |
| 2011-12-31 | ₩53.89 Billion | -- |